Grünenthal PRO and SHL Medical Join Forces for Enhanced Service
Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal, is embarking on an exciting partnership with SHL Medical. This collaboration aims to provide comprehensive final assembly services for the innovative Molly® autoinjectors. By combining their expertise, both companies will enhance the efficiency and quality of drug delivery systems.
Expanding Capacity for Autoinjector Assembly
As part of this collaboration, Grünenthal PRO plans to increase its assembly capacity at its facility in Origgio. This expansion includes installing additional assembly lines specifically for Molly® 1.0 and 2.25 mL autoinjector platforms, with completion aimed for 2026. The new assembly lines will be pre-validated, ensuring a quick and efficient process for pharmaceutical and biotech companies looking to expedite their time to market.
Commitment to Quality and Reliability
This strategic alliance brings significant benefits to SHL customers, including access to Grünenthal PRO's extensive experience and established reputation in providing high-quality contract manufacturing services. The integration of expert teams from both organizations promises to uphold the highest standards in drug delivery systems production.
The Importance of Speed-to-Market in Biopharma
Victor Barbosa, Executive Vice President of Global Operations at Grünenthal, emphasizes the critical importance of speed-to-market in the competitive biopharma landscape. He states, "With our extensive know-how in autoinjector final assembly and the upcoming high-speed lines, we are poised to offer agile, large-scale solutions. This collaboration with SHL further strengthens our capabilities, solidifying our position as a trusted CDMO partner for injectable therapies globally."
Innovative Design of the Molly® Autoinjector
The Molly® autoinjector represents a cutting-edge solution designed with modular platform technology that significantly reduces initial investments for pharmaceutical and biotech companies. This innovative product aims to accelerate development timelines while ensuring regulatory compliance. With a strong history of successful product approvals, Molly® is positioned to meet the evolving needs of future healthcare solutions.
A Strengthened Strategic Partnership
Markus Puusepp, Chief Growth Officer at SHL Medical, expressed enthusiasm about the partnership, noting, "Our collaboration with Grünenthal PRO has evolved from several successful projects, and we are thrilled to officially welcome them as a strategic ally. This collaboration not only strengthens our relationship but also adds significant value to our joint customers."
Procurement and Manufacturing Excellence
The assembly line dedicated to the Molly® autoinjector will be sourced from SHL Advantec, a frontrunner in providing exceptional precision tooling and advanced automation solutions for the healthcare sector. This partnership ensures that the assembly process will meet the highest standards of performance and quality.
The Vision of SHL Medical
SHL Medical, renowned as a global leader in advanced drug delivery systems, has established itself as the partner of choice for leading pharmaceutical and biotech companies. With a mission focused on enabling patient independence, SHL Medical is dedicated to patient-centric solutions in the design, development, and manufacturing of various injection technologies, including autoinjectors and pen injectors. The company’s commitment to sustainability is woven into every aspect of its design and production processes.
The Role of Grünenthal PRO in the Industry
Grünenthal PRO contributes significantly to the pharmaceutical industry by offering comprehensive end-to-end services in pharmaceutical assembly, packaging, and labeling. With a dedication to quality and rapid delivery, Grünenthal PRO plays a crucial role in supporting global pharmaceutical and biotech companies to bring their products swiftly to the market. Their advanced automation capabilities set them apart in the competitive landscape of contract manufacturing.
Frequently Asked Questions
What is the main goal of the partnership between Grünenthal PRO and SHL Medical?
The partnership aims to enhance final assembly services for the Molly® autoinjector, improving speed-to-market for pharmaceutical companies.
What facilities will Grünenthal PRO expand for this partnership?
Grünenthal PRO plans to expand its facility in Origgio by installing new assembly lines for the Molly® autoinjector.
Who is expected to benefit from this collaboration?
Both companies' customers, particularly in the biopharmaceutical sector, will benefit from improved assembly quality and speed.
What is Molly® known for in the healthcare market?
Molly® is recognized for its modular platform technology that helps reduce initial investments for drug developers.
Why is speed-to-market important in biopharma?
Speed-to-market is crucial as it enables companies to respond swiftly to market needs and regulatory changes, enhancing competitiveness.
